Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of N-(Ethoxycarbonyl)Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679019 | 0.92 | TSHR (0.57) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3889276 | 0.92 | TSHR (0.57) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL113765 | 0.92 | TSHR (0.57) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL11491904 | 0.90 | TSHR (0.55) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL28219889 | 0.90 | TSHR (0.55) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL27627315 | 0.89 | TSHR (0.53) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL1143951 | 0.85 | TSHR (0.50) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL23824721 | 0.84 | TSHR (0.49) | GAATSHRALDH1A1POLBHTT | |
| Hydrochloric Acid SCHEMBL28954178 | 0.84 | TSHR (0.49) | GAATSHRALDH1A1POLBHTT | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL28189103 | 0.84 | TSHR (0.73) | GAATSHRALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058346-A1 | Crystalline Modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-Hydroxyamidino- (L)- Phenylalanine 4-Ethoxycarbonylpiperazide And/Or Salts Thereof | WILEX AG (DE) | 2008-03-06 | — | — | US | claimed |
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2025-12-23 | — | — | US | disclosed |
| CN-117695284-B | Treatment of coronavirus infection | 红山生物医药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20240350461-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2024-10-24 | — | — | US | disclosed |
| CN-117695284-A | Treatment of coronavirus infection | 红山生物医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| CN-115515560-B | Treatment of coronavirus infection | 红山生物医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4117630-A1 | TREATMENT OF CORONAVIRUS INFECTION | RedHill Biopharma Ltd. (IL) | 2023-01-18 | — | — | EP | disclosed |
| CN-115515560-A | Treatment of coronavirus infection | 红山生物医药有限公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | GAA 1048/4885TSHR 4310/4885ALDH1A1 4491/4885 |
| US-20240350461-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | PRSS1, ACE, TMPRSS2 | GAA 1048/4885TSHR 4310/4885ALDH1A1 4491/4885 |
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | GAA 1048/4885TSHR 4310/4885ALDH1A1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.